Real World Prostate Cancer Registry
RWPCR
Patient Reported Data on Prostate Cancer Diagnosis, Management, and Outcome: Real World Prostate Cancer Registry
1 other identifier
observational
1,000
1 country
1
Brief Summary
Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological features, stages, and disease biology. The treatment options are dependent on the disease stage, its features, and the patient's condition and preferences. The disease outcome also varies significantly due to the previous heterogeneity of the features in addition to other social determinants of health. Therefore, it is critical to obtain real-world data that reflects the actual patterns of prostate cancer presentation, work up, management, and outcome. Real World Prostate Cancer Registry (RWPCR) aims at compiling real world data from patients presented with prostate cancer in the tristate area. The data collection will be prospective and longitudinal including patients' demographics and disease characteristics, work up, management, and outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 18, 2024
CompletedFirst Submitted
Initial submission to the registry
March 21, 2024
CompletedFirst Posted
Study publicly available on registry
April 9, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 18, 2034
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 18, 2034
May 31, 2025
May 1, 2025
10 years
March 21, 2024
May 27, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
To determine practice patterns for prostate cancer in the region.
Descriptive analysis of the disease risk groups, disease stages, and type of treatments provided to the patients (radiation, surgery, hormonal therapy).
10 years
Secondary Outcomes (2)
To determine progression free survival and overall survival of patients.
10 years
Prevalence of long term complications of prostate cancer treatment.
10 years
Eligibility Criteria
Residents of Ohio, Kentucky or Indiana
You may qualify if:
- All patients with pathologically confirmed primary prostate cancer
- Diagnosis since January 1st, 2023
- Acceptance to sign the consent form
- years old or older
- Resident of Ohio, Kentucky or Indiana
You may not qualify if:
- Having diagnosis of other cancer except squamous cell cancer of the skin
- Refusal to sign a consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cincinnati Cancer Advisors
Cincinnati, Ohio, 45212, United States
Related Publications (1)
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
PMID: 35020204BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2024
First Posted
April 9, 2024
Study Start
March 18, 2024
Primary Completion (Estimated)
March 18, 2034
Study Completion (Estimated)
March 18, 2034
Last Updated
May 31, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share